Van Lanschot Kempen Logo
  • Home
  • Solutions
  • News & knowledge
  • About us
Nov 2013
DBV 2 logo
Joint bookrunner
29.9 million

DBV

DBV Technologies is a French biotech company, whose lead product is a patch for the treatment of peanut allergy

  • DBV raised additional funding to finance its development strategy, while the transaction also allowed long-term holders to monetize part of their stakes.
  • Kempen & Co acted as Joint Bookrunner and placed 80% of the shares with US investors.

Fully focused on your future

Private Banking

  • Offices
  • Business professionals
  • Executives
  • Doctors
  • Entrepreneurs
  • Wealth management
  • Conditions
  • Private Banking - Belgium
  • Private Banking - Switzerland

Professional Solutions


Investment Management


Investment Banking



© Van Lanschot Kempen 2022
Security
Privacy & cookies
Disclaimer